Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance

In a recent study posted to bioRxiv* preprint server, researchers at Ohio State University examined the degree of neutralizing antibody (nAb) evasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron XBB.1.5, CA.3.1, and CH.1.1 subvariants.

23 Jan 2023

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

In a recent study published in The Lancet Microbe journal, researchers described the effectiveness of a modular capsid virus-like coronavirus disease 2019 (COVID-19) vaccination.

22 Jan 2023

Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

Researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations.

20 Jan 2023

Mutations may underlie how the most aggressive lymphomas arise and resist therapies

The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells, according to a multi-institutional preclinical study led by Weill Cornell Medicine investigators.

19 Jan 2023

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Researchers described the factors associated with protection, protection thresholds, and immunobridging in COVID-19 patients.

19 Jan 2023

Understanding the mechanisms involved in heart disease and cancers

In a crucial step towards understanding the mechanisms involved in cardiovascular disease and certain cancers, a Canadian led research team has succeeded in a world first: they've found the molecular mechanism by which the protein PCSK9 degrades the receptor of low density lipoproteins, the richest cholesterol particles in the bloodstream.

19 Jan 2023

How is long COVID diagnosed in adults?

In a recent study, researchers enlisted important points concerning post-coronavirus disease 2019 (COVID-19) or long COVID diagnosis among adults.

19 Jan 2023

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Researchers explored how mutations in emergent SARS-CoV-2 variants affect viral function, human immunity, and recognition by therapeutic antibodies.

19 Jan 2023

Berkeley Lights launches Beacon Select™, a new optofluidic system for cell line development

Berkeley Lights, Inc., a life sciences tools company, today announced the launch of the Beacon Select™, the company's new optofluidic system for cell line development (CLD).

From Bruker Cellular Analysis 19 Jan 2023

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001."

18 Jan 2023

Does COVID-19 cause adverse pregnancy and neonatal outcomes?

Early in the coronavirus disease 2019 (COVID-19) pandemic, pregnant women were thought to be at unusually high risk from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to the general population or non-pregnant women. However, later studies failed to agree on the extent and nature of the danger posed by the infection.

18 Jan 2023

T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service

Researchers performed an observational study among COVID-19 patients and their close contacts registered with the Bangkok home health care services in Thailand.

18 Jan 2023

Epitope mapping reveals the humoral responses against the main SARS-CoV-2 structural proteins in infected patients from Africa

Researchers performed immunoglobulin (Ig)M and IgG epitope mapping against 487 SARS-CoV-2 peptides.

18 Jan 2023

Study sheds new light on how the B cell academy mounts a diverse immune response

Cells jostling for a spot in a germinal center face a cutthroat admissions process. Formed after exposure to a pathogen or vaccine, germinal centers act as a kind of immune system training academy, helping B cells refine their response to the threat.

18 Jan 2023

The "Great Escape" by SARS-CoV-2 XBB.1

In a recent article published in the Lancet Microbe, researchers in the Netherlands and the United Kingdom quantified the antigenic diversity of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subvariants, BQ.1.1, BM.1.1.1, and XBB.1, all derivatives of the variant of concern (VOC) Omicron, which emerged in late 2022.

17 Jan 2023

Future COVID-19 control will require vaccines that induce better mucosal immunity

In a recent study posted to the medRxiv* preprint server, researchers in France explored the relationship between long-term immunoglobulin (Ig)-A response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and taste and smell disorders.

17 Jan 2023

What are the major findings of long COVID research?

Researchers explored existing literature on long coronavirus disease (COVID). They highlighted key immunological findings, similarities with other diseases, symptoms, and associated pathophysiological mechanisms, and diagnostic and therapeutic options, including COVID-19 vaccinations.

17 Jan 2023

Researchers explore immune responses to mpox infections

In new research, researchers demonstrated that individuals recovering from mpox virus (MPXV) infection have neutralizing antibodies that target MPXV antigens A35R and H3L.

17 Jan 2023

Study finds non-Omicron breakthrough infections elicit robust cross-neutralizing activity against Omicron variants across the antigenic barrier

Researchers assessed the effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with a non-Omicron variant on SARS-CoV-2 BA.4/5 neutralization.

17 Jan 2023

Mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months

High levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months.

16 Jan 2023

Antibody News and Research

Further Reading

SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

Mutations may underlie how the most aggressive lymphomas arise and resist therapies

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Understanding the mechanisms involved in heart disease and cancers

How is long COVID diagnosed in adults?

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Berkeley Lights launches Beacon Select™, a new optofluidic system for cell line development

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

Does COVID-19 cause adverse pregnancy and neonatal outcomes?

T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service

Epitope mapping reveals the humoral responses against the main SARS-CoV-2 structural proteins in infected patients from Africa

Study sheds new light on how the B cell academy mounts a diverse immune response

The "Great Escape" by SARS-CoV-2 XBB.1

Future COVID-19 control will require vaccines that induce better mucosal immunity

What are the major findings of long COVID research?

Researchers explore immune responses to mpox infections

Study finds non-Omicron breakthrough infections elicit robust cross-neutralizing activity against Omicron variants across the antigenic barrier

Mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo